Cell therapy of primary myopathies

Maurilio Sampaolesi, S. Biressi, R. Tonlorenzi, A. Innocenzi, E. Draghici, M. G. Cusella De Angelis, G. Cossu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Mesoangioblasts are multipotent progenitors of mesodermal tissues. In vitro mesoangioblasts differentiate into many mesoderm cell types, such as smooth, cardiac and striated muscle, bone and endothelium. After transplantation mesoangioblasts colonize mostly mesoderm tissues and differentiate into many cell types of the mesoderm. When delivered through the arterial circulation, mesoangioblasts significantly restore skeletal muscle structure and function in a mouse model of muscular dystrophy. Their ability to extensively self-renew in vitro, while retaining multipotency, qualifies mesoangioblasts as a novel class of stem cells. Phenotype, properties and possible origin of mesoangioblasts are addressed in the first part of this paper. In the second part we will focus on the cell therapy approach for the treatment of Muscular Dystrophy and we will describe why mesangioblasts appear to be promising candidates for this strategy.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalArchives Italiennes de Biologie
Volume143
Issue number3-4
Publication statusPublished - Sep 2005

Fingerprint

Mesoderm
Muscular Diseases
Cell- and Tissue-Based Therapy
Muscular Dystrophies
Striated Muscle
Endothelium
Smooth Muscle
Myocardium
Skeletal Muscle
Stem Cells
Transplantation
Phenotype
Bone and Bones
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sampaolesi, M., Biressi, S., Tonlorenzi, R., Innocenzi, A., Draghici, E., Cusella De Angelis, M. G., & Cossu, G. (2005). Cell therapy of primary myopathies. Archives Italiennes de Biologie, 143(3-4), 235-242.

Cell therapy of primary myopathies. / Sampaolesi, Maurilio; Biressi, S.; Tonlorenzi, R.; Innocenzi, A.; Draghici, E.; Cusella De Angelis, M. G.; Cossu, G.

In: Archives Italiennes de Biologie, Vol. 143, No. 3-4, 09.2005, p. 235-242.

Research output: Contribution to journalArticle

Sampaolesi, M, Biressi, S, Tonlorenzi, R, Innocenzi, A, Draghici, E, Cusella De Angelis, MG & Cossu, G 2005, 'Cell therapy of primary myopathies', Archives Italiennes de Biologie, vol. 143, no. 3-4, pp. 235-242.
Sampaolesi M, Biressi S, Tonlorenzi R, Innocenzi A, Draghici E, Cusella De Angelis MG et al. Cell therapy of primary myopathies. Archives Italiennes de Biologie. 2005 Sep;143(3-4):235-242.
Sampaolesi, Maurilio ; Biressi, S. ; Tonlorenzi, R. ; Innocenzi, A. ; Draghici, E. ; Cusella De Angelis, M. G. ; Cossu, G. / Cell therapy of primary myopathies. In: Archives Italiennes de Biologie. 2005 ; Vol. 143, No. 3-4. pp. 235-242.
@article{9b76f6d3cb2540689c5ddea5e6c7bb15,
title = "Cell therapy of primary myopathies",
abstract = "Mesoangioblasts are multipotent progenitors of mesodermal tissues. In vitro mesoangioblasts differentiate into many mesoderm cell types, such as smooth, cardiac and striated muscle, bone and endothelium. After transplantation mesoangioblasts colonize mostly mesoderm tissues and differentiate into many cell types of the mesoderm. When delivered through the arterial circulation, mesoangioblasts significantly restore skeletal muscle structure and function in a mouse model of muscular dystrophy. Their ability to extensively self-renew in vitro, while retaining multipotency, qualifies mesoangioblasts as a novel class of stem cells. Phenotype, properties and possible origin of mesoangioblasts are addressed in the first part of this paper. In the second part we will focus on the cell therapy approach for the treatment of Muscular Dystrophy and we will describe why mesangioblasts appear to be promising candidates for this strategy.",
author = "Maurilio Sampaolesi and S. Biressi and R. Tonlorenzi and A. Innocenzi and E. Draghici and {Cusella De Angelis}, {M. G.} and G. Cossu",
year = "2005",
month = "9",
language = "English",
volume = "143",
pages = "235--242",
journal = "Archives Italiennes de Biologie",
issn = "0003-9829",
publisher = "Pisa University Press",
number = "3-4",

}

TY - JOUR

T1 - Cell therapy of primary myopathies

AU - Sampaolesi, Maurilio

AU - Biressi, S.

AU - Tonlorenzi, R.

AU - Innocenzi, A.

AU - Draghici, E.

AU - Cusella De Angelis, M. G.

AU - Cossu, G.

PY - 2005/9

Y1 - 2005/9

N2 - Mesoangioblasts are multipotent progenitors of mesodermal tissues. In vitro mesoangioblasts differentiate into many mesoderm cell types, such as smooth, cardiac and striated muscle, bone and endothelium. After transplantation mesoangioblasts colonize mostly mesoderm tissues and differentiate into many cell types of the mesoderm. When delivered through the arterial circulation, mesoangioblasts significantly restore skeletal muscle structure and function in a mouse model of muscular dystrophy. Their ability to extensively self-renew in vitro, while retaining multipotency, qualifies mesoangioblasts as a novel class of stem cells. Phenotype, properties and possible origin of mesoangioblasts are addressed in the first part of this paper. In the second part we will focus on the cell therapy approach for the treatment of Muscular Dystrophy and we will describe why mesangioblasts appear to be promising candidates for this strategy.

AB - Mesoangioblasts are multipotent progenitors of mesodermal tissues. In vitro mesoangioblasts differentiate into many mesoderm cell types, such as smooth, cardiac and striated muscle, bone and endothelium. After transplantation mesoangioblasts colonize mostly mesoderm tissues and differentiate into many cell types of the mesoderm. When delivered through the arterial circulation, mesoangioblasts significantly restore skeletal muscle structure and function in a mouse model of muscular dystrophy. Their ability to extensively self-renew in vitro, while retaining multipotency, qualifies mesoangioblasts as a novel class of stem cells. Phenotype, properties and possible origin of mesoangioblasts are addressed in the first part of this paper. In the second part we will focus on the cell therapy approach for the treatment of Muscular Dystrophy and we will describe why mesangioblasts appear to be promising candidates for this strategy.

UR - http://www.scopus.com/inward/record.url?scp=22344437157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344437157&partnerID=8YFLogxK

M3 - Article

C2 - 16097501

AN - SCOPUS:22344437157

VL - 143

SP - 235

EP - 242

JO - Archives Italiennes de Biologie

JF - Archives Italiennes de Biologie

SN - 0003-9829

IS - 3-4

ER -